Evidence map›Paper›PMID 41621066›Full record

ArticleCell reports2026

FOXA1 mutations co-opt nascent transcription factor networks in partnership with androgen receptor to enhance prostate tumorigenicity.

Erik M Ladewig, Abbas Nazir, Tyler Park, Vinson B Fan, Zhendong Cao, Jacob Hawk, Lauren Kelly, Robert Tjian, Christina S Leslie, Charles L Sawyers

Abstract read
In one paragraph

Article in Cell reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Erik M LadewigComputational and Systems Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Abbas NazirHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Tyler ParkComputational and Systems Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Vinson B FanDepartment of Molecular & Cell Biology, University of California Berkeley, Berkeley, CA 94720, USA.
Zhendong CaoHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Jacob HawkHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Lauren KellyHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Robert TjianDepartment of Molecular & Cell Biology, University of California Berkeley, Berkeley, CA 94720, USA.
Christina S LeslieComputational and Systems Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Electronic address: lesliec@mskcc.org.
Charles L SawyersHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Electronic address: sawyersc@mskcc.org.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
The Center for Tumor-Immune Systems Biology at MSKCCU54CA274492 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI JOAN MASSAGUE · 2022 to 2026
$16.3M
Project 3: Analysis of intrinsic and extrinsic factors that promote prostate neuroendocrine differentiationP01CA265768 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Massimo Loda · 2022 to 2026
$13.4M
Role of ETS factors in specifying prostate luminal cell identity and androgen receptor dependenceR01CA193837 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI SAWYERS, CHARLES L. · 2015 to 2025
$4.7M
Understanding Resistance to Next Generation AntiandrogensR01CA155169 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI SAWYERS, CHARLES L. · 2012 to 2022
$3.8M
NCI NIH HHS P01 CA265768NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA155169NCI NIH HHS R01 CA193837NCI NIH HHS U54 CA274492
6 · The paper itself

Abstract

Mutations in the pioneer transcription factor FOXA1 occur in 10%-40% of prostate cancers and broadly alter chromatin accessibility. In a cohort of 874 primary and metastatic tumors, we confirm frequent Wing2 missense mutations and indels, as well as C-terminal truncating frameshifts. To define their functional impact, we performed single-nucleus multiome profiling in mouse prostate organoids expressing representative alleles, including overexpressed wild-type FOXA1. Each subgroup produces distinct chromatin and transcriptional changes, but all perturb epithelial lineage specification. Indel mutants promote basal-like states, whereas C-terminal truncations, Wing2 missense mutations, and elevated wild-type FOXA1 drive secretory L1-like luminal fates. Integrated RNA-seq, ATAC-seq, and ChIP-seq reveal that L1-like specification involves a hybrid androgen receptor/FOXA1 motif and cooperation with POU2F1. In vivo, these same alleles, combined with Trp53/Pten loss, shift tumor histology from basal-like to secretory luminal phenotypes.

Indexed as

CarcinogenesisHepatocyte Nuclear Factor 3-alphaMutationProstatic NeoplasmsReceptors, AndrogenTranscription FactorsAnimalsCell Line, TumorGene Expression Regulation, NeoplasticHumansMaleMiceOctamer Transcription Factor-1ProstateTumor Suppressor Protein p53FOXA1 protein, humanFoxa1 protein, mouseHepatocyte Nuclear Factor 3-alphaOctamer Transcription Factor-1Receptors, AndrogenTranscription FactorsTumor Suppressor Protein p53basalCP: cancerCP: molecular biologyFOXA1luminalPOU2F1prostate

Identifiers

PMID41621066
PMCPMC13050545

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.